Professional Bio

 Education
  • Ph.D. Pharmaceutical Economics, University of Southern California School of Pharmacy, Department of Pharmaceutical Economics and Policy, 2001
  • M.A. Economics, University of Colorado, Denver, CO, 1993
  • Certificate Graduate Studies (European Economic Policy), Katholieke Universiteit Te Leuven, Leuven, Belgium, 1992
  • B.A. Politics, Certificate Saint Ignatius Institute (Great Books program) University of San Francisco, San Francisco, CA, 1990
  • Oxford University (Keble College, Center for Medieval and Renaissance Studies), Oxford, England, 1989

Professional Memberships

  • International Society For Pharmacoeconomics and Outcomes Research (ISPOR)
  • Society for Medical Decision Making (SMDM)
  • International Society for Quality of Life Research (ISOQOL)
  • International Health Economics Association (IHEA)

Research & Scholarship

Research Interests

Cost-effectiveness analysis, pharmacoeconomics, utility assessment and health-related quality of life (HRQL)

Recent Publications

Sullivan, P.W., Ghushchyan, V., Bayliss, E. (2012). The impact of comorbidity burden on preference-based HRQL in the United States. Pharmacoeconomics, 30(5), 431–42.

McQueen RB, Ellis SL, Campbell JD, Nair KV, Sullivan PW2. Cost-Effectiveness of Continuous Glucose Monitoring and Intensive Insulin Therapy for Type 1 Diabetes. Cost Effectiveness and Resource Allocation. 2011, 9:13.

Padula WV, Sullivan PW2, Beyond migraines: how healthy are the 2012 presidential contenders? The Atlantic. August 3, 2011. http://www.theatlantic.com/politics/archive/2011/08/beyond-migraines-how-healthy-are-the-2012-presidential-contenders/242494/

Sullivan PW1. Are Utilities Bounded at 1.0? Implications for Statistical Analysis and Scale Development. Medical Decision Making. Mar 21 2011.

Sullivan PW1, Slejko MF, Sculpher MJ, Ghushchyan V. Catalogue of EQ-5D Scores for the United Kingdom. Medical Decision Making. 2011 Dec; 31(6):800-804.

Padula WV, Mishra MK, Makic MBF, Sullivan PW2. Improving the quality of pressure ulcer care with prevention: a cost-effectiveness analysis. Medical Care. 2011 Apr;49(4):385-392.

Sullivan PW1, Ghushchyan V, Bayliss E. The impact of comorbidity burden on preference-based HRQL in the United States. Pharmacoeconomics. 2011. In Press.

Sullivan PW1, Ghushchyan V, Slejko J, Belozeroff V, Globe D, Lin S. The burden of adult asthma in the United States: evidence from the Medical Expenditure Panel Survey. Journal of Allergy and Clinical Immunology. 2011 Feb;127(2):363-369.

Slejko JF, Page RL 2nd, Sullivan PW2. Cost-effectiveness of statin therapy for vascular event prevention in adults with elevated C-reactive protein: implications of JUPITER. Curr Med Res Opin. 2010 Oct;26(10):2485-97.

Sullivan PW1, Navaratnam P, Lorber, R, Shakar T. The cost-effectiveness of treatment with desloratadine in patients with persistent allergic rhinitis. Current Medical Research and Opinion. 2010. Jun;26(6):1389-97.

Sullivan PW1, Ghushchyan V, Huang XY, Globe DR. Influence of rheumatoid arthritis on employment, function, and productivity in a nationally representative sample in the United States. J Rheumatol. 2010 Mar;37(3):544-9.

Recent Presentations

Invited Presentations:

Sullivan, P.W. (2013). Poor Asthma Control Results in Decreased Productivity and More Exacerbations. AAAAI Annual Meeting. San Antonio, TX.

Ghushchyan, V.H., Sullivan, P.W. (May 1, 2011) Expected changes in health care utilization due to patient protection and affordable care act, International Society for Pharmacoeconomics and Outcomes Research, Baltimore, MD.

"Reducing the Burden of Persistent Allergic Rhinitis". Antihistamine Summit. Vienna, Austria. February 4-6, 2010.

"Using A Catalogue Of EQ-5D Scores To Model QALYs For Cost-Effectiveness Analyses." Amgen, Inc. Thousan Oaks, CA. November 2009.

Peer-reviewed Podium Presentations:

Slejko J, Sullivan PW, Page R, Nair K, Campbell J. "Modeling medication adherence behavior in cost-effectiveness analysis: the jupiter example". Society for Medical Decision Making. October 2011. Chicago, IL.

"Using A Catalogue Of EQ-5D Scores To Model QALYs For Cost-Effectiveness Analyses." ISPOR. Atlanta, GA. May 18 2010.

"Incorporating Tariff-Level Uncertainty Around Estimates From The Catalogue Of EQ-5D Scores." ISPOR. Atlanta, GA. May 18 2010.

"Comparison Of Health State Utility Estimates In Cost-Effectiveness Analysis" (Julia Slejko PhD advisee). ISPOR. Atlanta, GA. May 18 2010.

"Under Pressure--Reducing Hospital-acquired Pressure Ulcer Rates with Prevention: A Cost-effectiveness Analysis" (Bill Padulla, PhD advisee) 21st Annual Rocky Mountain Regional Multidisciplinary Research & Evidence-Based Practice Symposium. Denver, CO March 5 2010.

"Modeling Outcomes in Persistent Allergic Rhinitis (PER)". World Allergy Congress. Buenos Aires, Argentina. December 2009.

"Self-Rated Health and Depression" (Julia Slejko, PhD Advisee). International Society for Quality of Life Research (ISOQOL). Oct 29 2009.

"Comparative effectiveness without head-to-head trials: indirect comparisons using primary and published clinical trial data". (Co-author with Signorovich J). ISPOR Orlando, FL. May 19 2009.

Peer-reviewed Posters:

Sullivan PW, Fraessdorf M, Feuring M, Schulman S, Hass B. Health-related quality of life after venous thromboembolism. ISPOR. Madrid, Spain. November 2011.

Sullivan PW, Ghushchyan VH. Can utilities exceed 1.0? Empirical evidence of the ceiling effect. ISPOR. Baltimore, MD. May 2011.

Ghushchyan VH, Sullivan PW. Expected changes in health care utilization due to patient protection and affordable care act. ISPOR. Baltimore, MD. May 2011.

Peter Clapp, Matthew G. Fete, Patrick Sullivan, Marianne McCollum, Jason Brunner, and Charlotte Ricchetti. A New Tool for Peer Assessment in Team Based Learning. Team-Based Learning in Higher Education. Las Vegas, NV. March 2011.

Jason M. Brunner, Marianne McCollum, Peter Clapp, Matthew Fete, Patrick Sullivan, Charlotte Ricchetti. The Assessment of a Multi-method Peer Evaluation Tool. Team-Based Learning in Higher Education. Las Vegas, NV. March 2011.

Sullivan PW, Ghushchyan V, Slejko J, Belozeroff V, Globe D, Lin S. The burden of adult asthma in the United States: evidence from the Medical Expenditure Panel Survey. Amgen Observational Research Conference. October 2010.

Slejko J, Page R, Sullivan PW. Statin therapy is cost-effective for vascular event prevention in adults with elevated c-reactive protein: implications of JUPITER. American College of Cardiology. Atlanta, GA. March 15, 2010.

Sullivan PW, Ghushchyan VH, Sculpher M. A catalogue of EQ-5D scores for the UK. ISPOR. Paris, France. November 2009.

Slejko J, Page R, Sullivan PW. Cost-effectiveness of statin therapy for CHD prevention in adults with elevated c-reactive protein: implications of JUPITER results. Society for Medical Decision Making. October 19, 2009. Los Angeles, CA.

McQueen R, Ellis S, Sullivan PW. Cost-effectiveness of continuous glucose monitoring and intensive insulin therapy for type 1 diabetes. Society for Medical Decision Making. October 19, 2009. Los Angeles, CA.

Padulla W, Patel M, Sullivan PW. Acost-effectiveness analysis for the prevention of hospital-acquired pressure ulcers. Society for Medical Decision Making. October 19, 2009. Los Angeles, CA.

McQueen R, Ellis S, Sullivan PW. Cost-effectiveness of continuous glucose monitoring and intensive insulin therapy for type 1 diabetes. Society for Medical Decision Making. October 19, 2009. Los Angeles CA.

Slejko, J, Page R, Sullivan PW. Medical expenditures attributable to coronary artery disease in the United States. ISPOR. May 19, 2009. Orlando, FL.

Padula WV, Sullivan PW. The Health of the President. The Third Annual Health Disparities Conference. April 19-21, 2009, New Orleans, LA.

Awards & Recognition

Principal Investigator, Exploring Outcomes and Control in Asthma II, Amgen, October 2012 - January 2016, $87,615, 2012-2016

Principal Investigator, Observational Study for Asthma Control & Outcomes (OSACO), Amgen, October 2013 – July 2016, $1,770,434 ($374,117 direct to Regis), 2013-2016

Senior Advisor to Vahram Ghushchyan (Principal Investigator). Characterizing Uncertainty in Utility Instruments. PhRMA Foundation – Research Starter Award,  $60,000, 2012-2013

"Observational Study for Asthma Control & Outcomes (OSACO)." Principal Investigator (.20 FTE), $1,132,602. Funded by Amgen, 2010-2014

"Exploring Outcomes and Control in Asthma." Principal Investigator (.50 FTE), $238,358. Funded by Amgen, 2008-2010

"Quantifying the Burden of Psoriasis in the U.S." Principal Investigator (.36 FTE), $164,809. Funded by Amgen, 2008-2009